Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai Corporation and its US subsidiary Eisai Incorporated have announced that the US District Court of New Jersey has ruled in company's favor with respect to Eisai's motion for a preliminary injunction in its patent infringement lawsuit against Teva Pharmaceuticals and its division Gate Pharmaceuticals, concerning Aricept.
Subscribe to our email newsletter
As previously announced, Eisai has filed the infringement actions in December 2005 contesting Teva’s submission of an abbreviated new drug application (ANDA) to the FDA for Aricept (donepezil hydrochloride). Aricept, an acetylcholinesterase inhibitor is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer’s type.
Hajime Shimizu, chairman and CEO of Eisai Corporation of North America and Eisai, said: “We are pleased with the court’s preliminary injunction decision to prevent the sale of Teva’s generic product before the expiration of the donepezil composition of matter patent. We will continue to actively protect our intellectual property throughout the world.”